A study conducted by Rohaan et al. compared the efficacy of TIL against ipilimumab, an anti-cytotoxic T-lymphocyte-4 (CTLA-4) antibody in patients with advanced melanoma [80]. This evidence concerns the gene CTLA4 and melanoma.